Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed primary leiomyosarcoma (LMS) of the uterus
• * Advanced, persistent, or recurrent disease that is refractory to curative therapy or established treatments
• At least 1 unidimensionally measurable target lesion
• * At least 20 mm by conventional techniques (e.g., palpation, plain x-ray, CT scan, or MRI) OR
• * At least 10 mm by spiral CT scan
• * Tumors within a previously irradiated field are designated as non-target lesions
• Ineligible for a higher priority Gynecologic Oncology Group protocol (if one exists), including any active phase III protocol for the same population
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• GOG 0-2
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hepatic:
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• SGOT no greater than 2.5 times ULN
• Alkaline phosphatase no greater than 2.5 times ULN
• Renal:
• Creatinine no greater than 1.5 times ULN
• Other:
• No active infection requiring antibiotics
• No grade 2 or greater sensory or motor neuropathy
• No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• No prior cytotoxic chemotherapy for LMS of the uterus
• Endocrine therapy:
• At least 1 week since prior hormonal therapy for LMS of the uterus
• Concurrent hormone replacement therapy allowed
• Radiotherapy:
• See Disease Characteristics
• Recovered from prior recent radiotherapy
• Surgery:
• Recovered from prior recent surgery
• Other:
• Recovered from other prior recent therapy
• No prior cancer treatment that would preclude study therapy